Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an Intellectual Property (IP) agreement with the University of Southampton, UK
Telix is pleased to announce that its wholly-owned subsidiary TheraPharm GmbH has com
pleted an Intellectual Property (IP) agreement with the University of Southampton, UK, thereby granting Telix exclusive access to a key clinical data package relating to 90Y-besilesomab, a therapeutic product Telix intends to develop for bone marrow conditioning (BMC) in patients undergoing hematopoietic stem cell transplant (HSCT) for the treatment of blood cancers (hematologic malignancies) and various related conditions.
The Agreement specifically provides Telix the exclusive rights to clinical data generated in the University of Southampton’s Targeted Radiotherapy for AL Amyloidosis (‘TRALA’) clinical trial, led by Dr. Kim Orchard, Senior Lecturer and Consultant Hematologist at the University Hospital Southampton. The Phase I TRALA trial, which has completed patient recruitment, evaluated the safety and toxicity of 90Y-besilesomab as the sole bone marrow conditioning agent in patients undergoing hematopoietic stem cell transplant for the treatment of systemic amyloid light chain amyloidosis (‘SALA’).
Early observations from the TRALA study have demonstrated promising safety and efficacy results for 90Y-besilesomab as a BMC agent in patients with SALA, with final results from the TRALA trial expected to be reported in January 2021. 90Y-besilesomab has been granted orphan drug designation (ODD) status in Europe for the broad indication of BMC for HSCT and has significant potential for fast-track development for the treatment of SALA.
For more on the collaboration please see full ASX release here.